Q2 Earnings Estimate for Neuronetics Issued By William Blair

Neuronetics, Inc. (NASDAQ:STIM) – Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Neuronetics in a research note issued to investors on Tuesday, May 6th. William Blair analyst M. Andrew now forecasts that the company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.08). The consensus estimate for Neuronetics’ current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics’ Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.10) EPS.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $31.98 million for the quarter, compared to analyst estimates of $29.07 million. Neuronetics had a negative return on equity of 141.24% and a negative net margin of 50.09%.

Separately, Canaccord Genuity Group raised their price target on Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 5th.

Neuronetics Stock Performance

STIM stock opened at $4.43 on Friday. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.92. The firm has a market cap of $291.56 million, a PE ratio of -3.60 and a beta of 1.92. The stock has a 50-day moving average price of $4.25 and a 200-day moving average price of $2.84.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of STIM. Larson Financial Group LLC purchased a new position in shares of Neuronetics during the first quarter valued at approximately $25,000. Geode Capital Management LLC increased its position in Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after purchasing an additional 8,466 shares during the period. KPP Advisory Services LLC bought a new position in Neuronetics in the 1st quarter worth $37,000. Presidio Capital Management LLC purchased a new stake in shares of Neuronetics in the 1st quarter worth about $44,000. Finally, David J Yvars Group boosted its stake in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

Insider Activity at Neuronetics

In related news, CFO Stephen Furlong sold 17,307 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $4.11, for a total transaction of $71,131.77. Following the transaction, the chief financial officer now owns 454,420 shares of the company’s stock, valued at approximately $1,867,666.20. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP William Andrew Macan sold 12,175 shares of the business’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $46,630.25. Following the completion of the sale, the executive vice president now directly owns 388,647 shares of the company’s stock, valued at approximately $1,488,518.01. This trade represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,369 shares of company stock valued at $358,929 over the last 90 days. 8.70% of the stock is owned by insiders.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.